AZD7507 - 10mM in DMSO , CAS No.1041852-85-0

CAS: 1041852-85-0 Cat. No.: A655605 Formule: C₂₃H₂₇FN₆O₃ Poids moléculaire: 454.50 Numéro CE: 682-437-2 PubChem CID: 25001557

GRADE & PURITY 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Vue d’ensemble

AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.

In Vitro

AZD7507 (Compound 31) inhibits the proliferation of 3T3 cells engineered to express CSF-1R and stimulated with CSF-1 (IC 50 , 32 nM), shows inhibitory activity against hERG and NaV1.5, with IC 50 s of >30 and 26 μM. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AZD7507 has good rat oral PK, with in vivo clearance of 7 mL/min/kg and 42% bioavailability. In the canine L-type Ca channel assay, the IC 50 is >20 μM . AZD7507 significantly decreases the number of CD68 + macrophages in mice, and also reduces the volume and mass in mice bearing CC-LP-1 and SNU-1079 cells, but not WITT-1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal administration

Mice Male CD1 nude mice are injected subcutaneously with 5 × 10 5 human ICC cells from human cell line WITT-1, CC-LP-1, or SNU-1079 (n = 24 in all cases) suspended in culture media/RGF Matrigel (Gibco) mix (1:1). Cells are engrafted bilaterally in the flank and allowed to form tumors over 3 weeks. Once palpable tumors have formed, mice are randomized into 3 groups using GraphPad online software. Xenografted mice are injected with liposomal clodronate at 4 μL/g intravenously. The control for this treatment is saline alone or liposomes not containing clodronate (both given at 4 μL/g intravenously). All of these treatments are given every 48 hours for 3 weeks. CSFR1 inhibitors AZD7507 and GW2580 are made up in sterile water containing 0.5% methylcellulose and 0.1% Tween-80 . AZD7507 is given twice daily at 100 mg/kg , whereas GW2580 is given daily at 160 mg/kg. Control animals are given water containing 0.5% methylcellulose and 0.1% Tween-80. ICG-001 (5 mg/kg) or C-59 (20 mg/kg) is given by intraperitoneal injection. The vehicle for this is physiological saline. Control animals are given vehicle alone. In all cases inhibitors and vehicle are given 3 times per week . aladdin has not independently confirmed the accuracy of these methods. They are for reference only.

IC50& Target:CSF-1R

Specifications

Spécifications et pureté

10mM in DMSO

Mécanismes biochimiques et physiologiques

AZD7507 is a potent and orally active CSF-1R inhibitor, with antitumor activity.

Conditions de stockage de stockage

Store at -80°C

Expédié en

Dry ice packs + Cold packs

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Type d'action

INHIBITOR

Noms et identifiants

• Isomères SMILES: CC1=CC(=C(C=C1)NC2=C(N=NC3=CC(=C(C=C32)N4CCN(CC4)CCO)OC)C(=O)N)F
• CAS alternatif: 1041852-85-0
• PubChem CID: 25001557
• Termes d'entrée MeSH: AZD7507
• Poids moléculaire: 454.50

Application Protocols

No manufacturer-validated protocols are provided for this product. The following is general guidance for small-molecule handling and assay setup; adapt and validate for your system.

• Preparation of DMSO stock (example workflow):
  • Equilibrate vial from −80°C in a desiccated environment to avoid condensation.
  • Weigh the required amount quickly, cap promptly.
  • Dissolve in anhydrous DMSO to the target concentration (e.g., 10–50 mM, as solubility allows); vortex and sonicate briefly if needed.
  • Optionally sterile-filter through 0.2 µm PTFE for cell-based work.
  • Aliquot into low-bind tubes; store at −20 to −80°C per your stability assessment.
• Assay dosing:
  • Prepare serial dilutions in DMSO, then spike into buffer/media to reach the final dosing concentrations, ensuring the vehicle percentage is constant across wells.
  • Include vehicle-only and, where applicable, positive/negative controls.
• Analytics:
  • Confirm concentration by UV or LC–MS using a calibration curve prepared from the same stock; apply purity correction if using area% purity from CoA.

All parameters above are illustrative and not item-specific. For any standardized or regulated testing, develop and document a validated, fit-for-purpose protocol.

Biological Roles

• Intrinsic biological role: AZD7507 is a synthetic, research-use small molecule and has no known endogenous biological role.
• Mechanistic context: The specific molecular target and mode of action for AZD7507 are not provided in this listing. If you intend to use it as a probe, consult primary literature corresponding to CAS 1041852-85-0 / CID 25001557 and verify reported targets, potency, and selectivity under your assay conditions.
• Use in discovery biology (general guidance):
  • Establish a robust concentration–effect relationship (e.g., EC50/IC50) in at least two orthogonal assays to confirm activity.
  • Perform counterscreens to rule out assay interference (fluorescence quenching, redox cycling, aggregation). Consider detergent controls and dynamic light scattering if aggregation is suspected.
  • Quantify compound stability in the chosen biological matrix (serum, cell media, lysate) using LC–MS and monitor for adsorption to plastics.
• Selectivity profiling: For probe-level studies, run a panel against related targets (biochemical or phenotypic). Utilize chemoproteomics or thermal shift profiling to strengthen target engagement claims.
• Data stewardship: Record batch ID/lot, CoA purity, stock concentration, solvent percentage, and exposure times for reproducibility.

Note: All uses are strictly for laboratory research. No medical, diagnostic, or therapeutic claims are made or implied.

Buffer Applications

AZD7507 is not a buffering reagent. However, it may be introduced into buffered biological systems as a small-molecule stock.

Practical guidance (general, not item-specific):

• Stock preparation: Dissolve in anhydrous DMSO to a convenient concentration (e.g., 10–50 mM, as solubility allows). Verify clarity and absence of particulates.
• Dilution into buffer: Add the DMSO stock to the target buffer (e.g., PBS, HEPES, Tris) under vortexing to avoid local supersaturation. Typical final DMSO levels are maintained at ≤0.1–1% v/v depending on assay tolerance.
• Order of addition: Add compound last to complex media containing proteins/serum to reduce precipitation; pre-warming the buffer to 25–37°C can aid solubilization if compatible with your assay.
• Adsorption control: Use low-bind tubes/plates for low-nanomolar work; pre-rinse plastics with buffer containing a small amount of protein or surfactant where appropriate.
• pH considerations: Because AZD7507’s pKa profile is not specified, avoid extreme pH unless validated. Maintain buffers within physiological ranges unless your protocol dictates otherwise.
• Stability checks: Monitor for precipitation or degradation by analytical LC over the assay timeframe. Prepare fresh dilutions as needed to ensure consistent exposure.

For exact solubility limits and pH-dependent behavior, consult the CoA/Spec Sheet or determine empirically in your laboratory.

Green Alternatives

As AZD7507 is a discrete small molecule rather than a process solvent or reagent, “green alternatives” considerations primarily concern solvent choices for dissolution, handling, and analytical work.

General guidance (not item-specific):

• Prefer lower-toxicity, higher-recovery solvents for preparative tasks. Where compatible with solubility, consider ethyl acetate, 2-MeTHF, or isopropanol instead of chlorinated solvents.
• For stock solutions, DMSO is often unavoidable due to solvency; minimize volumes, maximize re-use of vials, and segregate waste streams for proper disposal.
• Employ microscale assays to reduce compound and solvent consumption. Opt for high-throughput, low-volume plate formats where feasible.
• Use closed systems and solvent capture during evaporation to reduce emissions; favor LC–MS mobile phases based on water–acetonitrile over water–methanol if it improves energy efficiency via lower backpressure and faster runs in your setup.

Illustrative solvent comparison (generic):

• DCM/CHCl3 vs 2-MeTHF/EtOAc: greener alternatives reduce halogenated waste but may alter selectivity/solubility; validate recovery and purity.
• DMF/DMAc vs Cyrene/GBL: bio-based dipolar aprotics can replace amide solvents in some steps; assess stability of the compound in these media.

Recommendation:

• Map the complete solvent lifecycle (procurement → use → recovery/disposal) in your workflow with AZD7507 to identify the highest-impact substitutions without compromising data quality.

Pharmaceutical Uses

No pharmacopeial status, dosage form information, or excipient role is provided for this product. AZD7507 is supplied strictly for laboratory research use.

Relevant uses in a pharmaceutical R&D context (general guidance):

• Reference standard: Can serve as an internal or external standard for developing and validating LC–MS/UPLC assays (specificity, linearity, precision, accuracy) after assigning purity-corrected concentrations via qNMR or mass balance.
• Discovery tool: Potential use as a tool compound in target validation or SAR benchmarking if a literature target exists for AZD7507; confirm identity/purity and verify activity in-house.
• Stability studies: Employ as a test article for forced-degradation pathway elucidation (acid/base, oxidative, thermal, photolytic) to inform stability-indicating method development for related chemotypes.
• Formulation screening (preclinical): Small-scale solubilization/excipient screens (co-solvents, cyclodextrins, lipid-based systems) may be conducted to support in vitro/in vivo research; any such work must remain within non-clinical, research-only boundaries.

Compliance and documentation:

• Maintain traceable records of lot number, CoA, and analytical confirmation (HPLC/LC–MS/NMR) in your quality system.
• This material is not intended for human or veterinary use, diagnostics, or clinical applications.

Physical Properties

Item-specific physical constants and solution properties are not supplied in this listing.

• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point, boiling point, density, refractive index, pKa, logP/logD, UV-Vis λmax: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General laboratory guidance (literature/good practice, not item-specific):

• Drug-like discovery compounds are commonly supplied as solids and are most often reconstituted in anhydrous DMSO to prepare concentrated stocks (e.g., 10–50 mM), followed by dilution into assay buffers. Actual solubility limits must be verified empirically for AZD7507.
• If solubility screening is needed, consider a tiered approach: DMSO → DMF → acetonitrile → ethanol → aqueous buffer with co-solvent/surfactant (e.g., 0.01–0.1% Tween-80), assessing clarity and stability over time.
• Thermal behavior (melting/softening) and hygroscopicity should be determined experimentally on receipt if your workflow is sensitive to water uptake.

Note: Where precise physical constants are required for method development, please consult the CoA/Spec Sheet accompanying your lot or retrieve literature data tied to CAS 1041852-85-0 / CID 25001557 and validate under your laboratory conditions.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

Interpretation and guidance:

• In the absence of a stated grade, AZD7507 should be treated as a research-use reference compound. The actual purity specification, residual solvent profile, and analytical release tests are defined on the lot-specific CoA.
• For small-molecule screening and mechanistic studies, typical documentation includes: HPLC/UPLC purity, LC–MS identity, and where appropriate, NMR verification. Confirm acceptance criteria on the CoA prior to use in critical assays.
• If your application is highly UV-sensitive (e.g., LC–UV quantitation), request UV cut-off/trace impurity information or run a blank DAD scan of the solvent system with the compound to assess baseline absorbance.
• If stabilizers, salt form, or polymorph are relevant to your protocol, verify these on the Spec Sheet/CoA. None are specified in this listing.
• For regulated workflows (GLP/GMP), establish suitability via internal qualification: system suitability standards, orthogonal purity checks, and stability-indicating methods.

Recommendation:

• Retain and cite the lot-specific CoA in your ELN. If tighter impurity thresholds (e.g., for quantitative bioanalytical method validation) are required, contact technical support for available lots or custom material prepared to your specification.

Reaction and Applications

This product is a finished small-molecule research compound rather than a synthetic reagent. Accordingly, its primary use is as a reference/probe candidate in discovery and method-development contexts rather than as a coupling partner or catalyst.

Potential laboratory applications (general, not item-specific):

• Biochemical and cell-based assays: Use as a blinded or known control compound in high-content screens or targeted assays once its identity/purity are verified from the CoA. Determine concentration–response relationships and media compatibility.
• Analytical reference: Calibration standard for LC–MS/UPLC method development and stability studies once extinction coefficients or MS response factors are established empirically.
• Target-validation workflows: If a literature target is established for AZD7507 (consult primary sources via CAS 1041852-85-0 / CID 25001557), incorporate orthogonal readouts and counter-screens to confirm on-target activity and chemotype specificity.

Practical notes:

• Prepare concentrated DMSO stocks and avoid moisture ingress. Aliquot to minimize freeze–thaw.
• For long assays, run vehicle controls matched to the final solvent percentage and conduct solubility/stability checks over the assay duration.
• Include adsorption controls if working at low nanomolar levels; precondition plastics or use low-bind labware to mitigate nonspecific binding.

Because no manufacturer application notes are provided for this item, design and validate all conditions empirically within your assay system.

Reaction Conditions

Classical reaction condition guidance is not directly applicable because AZD7507 is not supplied as a reagent for use in chemical transformations. Nevertheless, certain handling and formulation “conditions” are commonly optimized for small-molecule probe work.

General laboratory conditions (not item-specific):

• Stock preparation: Dissolve in anhydrous DMSO at a validated concentration. Gentle warming (25–40°C) and sonication can aid dissolution; avoid prolonged heating.
• Aqueous dilution: Add stock to buffered media under vigorous mixing to minimize precipitation. Maintain final DMSO within your assay’s tolerance (often ≤0.1–1%).
• Light/oxygen sensitivity: In the absence of item-specific data, handle under ambient light with protection as prudent (amber vials), and minimize air/water exposure if working over extended periods.
• Stability assessments: Run small-scale time-course LC–MS to confirm stability in your chosen solvent/buffer at experimental temperature (e.g., 4, 25, 37°C). Define hold times for assay plates and autosampler vials.
• Adsorption control: Use low-bind plastics or silanized glass if signal loss is observed at low concentrations.

If you intend to use AZD7507 within a chemical reaction (e.g., for conjugation), first obtain the exact structure (via CAS 1041852-85-0 / CID 25001557) and determine functional-group compatibility and required catalysts/solvents based on that verified structure.

Safety and Handling

Safety details specific to this item are not populated in the listing and must be confirmed in the SDS for your lot.

• GHS classification, pictograms, signal word, H-statements: Not specified for this item; refer to SDS.
• General PPE: Laboratory coat, safety glasses, and appropriate chemical-resistant gloves. Use in a chemical fume hood to avoid inhalation exposure to powders or solvent vapors.
• Storage conditions (item-specific): Store at −80°C (per Product Data). Maintain tightly closed in the original container; protect from light and moisture as prudent practice for discovery compounds.
• Shipping (item-specific): Shipped on dry ice packs + cold packs to maintain low temperature during transit.
• Handling tips (good practice):
  • Allow vials shipped on dry ice to equilibrate in a desiccator at 2–8°C before opening to minimize condensation.
  • If preparing DMSO stocks, use dry, oxygen-free conditions where feasible to maximize stability. Filter solutions (0.2 µm PTFE) if particulates are observed.
  • Avoid repeated freeze–thaw cycles by aliquoting stocks.
• Incompatibilities (general): Avoid strong oxidizers and strong acids/bases unless compatibility has been established. Do not heat-seal or autoclave sealed vials containing organic solvents.
• First aid (overview; consult SDS): Move to fresh air if inhaled; rinse skin/eyes with water for at least 15 minutes upon contact; seek medical attention if irritation persists; if ingested, rinse mouth and seek medical advice.

Always defer to the official SDS for authoritative hazard and response information.

Solvent Selection

Item-specific solubility data are not provided. The following workflow reflects common best practices for drug-like small molecules and should be validated for AZD7507 in your lab.

• Primary stock solvent (general): Anhydrous DMSO is the most frequent first choice due to broad solvating power and assay compatibility at low final percentages.
• Alternative organic solvents: DMF, acetonitrile, methanol/ethanol, or 2-methyltetrahydrofuran (2-MeTHF) for preparative operations; verify stability.
• Aqueous work: Prepare a concentrated DMSO stock, then dilute into assay buffer (PBS, HEPES, Tris, etc.) while vortexing; keep final DMSO typically ≤0.1–1% v/v as dictated by your assay tolerance.
• Surfactant-assisted systems: If precipitation occurs upon dilution, consider 0.01–0.1% nonionic surfactant (Tween-80 or Pluronic F-68) and/or serum proteins for biochemical/cellular assays, subject to control experiments.

Quick comparison (general guidance):

• DMSO: highest solvency, excellent for small stocks; may affect some enzymes/cells at >0.5–1%.
• DMF: similar solvency to DMSO; assess toxicity and compatibility with biology.
• Acetonitrile: moderate solvency; volatile and LC-MS friendly; lower aqueous miscibility impact after dilution.
• Alcohols (MeOH/EtOH): useful for analytics; can perturb membranes/receptors in cells.

Practical tips:

• Warm gently (25–40°C) and sonicate to aid dissolution; avoid prolonged heating.
• Document the maximum soluble concentration and clarity window upon dilution to your specific buffer system.
• Filter stocks if necessary using solvent-compatible membranes (PTFE for organics).

Storage and Reconstitution

• Storage (item-specific): Store at −80°C. Keep container tightly closed. Protect from moisture; use a desiccant if long-term storage outside a freezer is required during weighing.
• Shipping (item-specific): Dispatched on dry ice packs + cold packs to maintain low temperature through transit.
• Reconstitution solvent: Not specified for this item; refer to CoA/Spec Sheet. General practice for small molecules is to use anhydrous DMSO for concentrated stocks, then dilute into assay buffer.
• Aliquoting: Divide reconstituted stock into single-use aliquots to avoid freeze–thaw cycles. Use low-bind vials to reduce adsorption at low concentrations.
• Freeze–thaw guidance: Minimize cycles. If repeated access is required, consider a working aliquot stored at −20°C for short-term use and a master stock at −80°C.
• Stability: Not specified for this item; refer to CoA/Spec Sheet. Establish in-house stability by LC–MS/UPLC under your storage and assay conditions (light, temperature, solvent, and pH).
• Thawing/handling tips: Thaw on ice or at room temperature as appropriate; briefly vortex to ensure homogeneity before use. Allow containers equilibrated from deep-cold storage to come to 2–8°C in a desiccator before opening to minimize moisture uptake.

Always consult the lot-specific CoA and SDS for definitive instructions and safety information. This product is for research use only.

Structure and Identity

AZD7507 is a cataloged small-molecule research compound. Public registry identifiers are provided to aid cross-referencing; item-specific structural details are not included in this listing.

• Product name: AZD7507 (SKU: A655605)
• CAS: 1041852-85-0
• PubChem CID: 25001557
• Category: Small molecules and compound libraries (research use)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general notes for small-molecule research compounds):

• Many “AZD-” series molecules are drug-like, heteroatom-containing scaffolds designed for target modulation in discovery research. The exact functional groups, ring systems, and stereochemical elements for AZD7507 should be confirmed directly from the CoA/SDS or primary literature linked to the above identifiers.
• If you require a 2D structure, we recommend retrieving it using the provided CAS or PubChem CID in your structure database (e.g., PubChem, ChemSpider, Reaxys) and attaching it to your internal project record.

2D structure description (generic guidance):

• For documentation and ELN traceability, capture heteroatoms, ring topology (aromatic vs. aliphatic), linker motifs, and any chiral centers reported in the definitive structural record obtained from the above identifiers.

Synthetic Utility

AZD7507 is a finished small molecule intended for use as a research compound or analytical reference, not as a general synthetic building block.

• As a reagent/auxiliary: Not typically employed. There is no item-specific functionality disclosed that would make it a common coupling partner, ligand, or catalyst. If your project contemplates derivatization (e.g., probe synthesis, biotinylation, photoaffinity tags), confirm functional handles from the definitive structure (via CAS/CID) and plan protecting-group strategies accordingly.
• Analytical utility: Serves as a calibration or system suitability standard in chromatographic or mass-spectrometric methods after in-house qualification.
• Derivatization considerations (general): If aromatic heterocycles or amine/alcohol handles are present (to be confirmed from structure), late-stage diversification by N- or O-acylation/alkylation, Suzuki/SONOGASHIRA couplings (if halides/boronates are present), or amide couplings could be explored to generate tool derivatives. All such proposals require verification of the actual structure and compatibility.

Conclusion:

• Treat AZD7507 as a terminal compound. Unless structural data confirm accessible reactive handles, it is not recommended as a routine synthetic intermediate. Any synthetic use should be preceded by a careful structure and reactivity assessment based on the authenticated structural record.

Target Specificity

• Target/epitope: Not specified for this item; refer to primary literature and CoA.
• Selectivity profile: Not specified for this item; consult peer-reviewed sources linked to CAS 1041852-85-0 / CID 25001557.
• Potency metrics (IC50/Ki/Kd/EC50): Not specified for this item; verify experimentally in your assay system if literature data are to be referenced.
• Off-targets and counterscreens: Not specified for this item; design appropriate orthogonal and counterscreen panels to establish specificity.

Note: AZD7507 is a small molecule, not an antibody or protein reagent; classical immuno-specificity parameters (clone, isotype, species reactivity) do not apply.